Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

AIMS: Mineralocorticoid receptor antagonists (MRAs) improve outcomes in patients with heart failure and reduced left ventricular ejection fraction (HFrEF), but their use is limited by hyperkalaemia and/or worsening renal function (WRF). BAY 94-8862 is a highly selective and strongly potent non-stero...

Descripción completa

Detalles Bibliográficos
Autores principales: Pitt, Bertram, Kober, Lars, Ponikowski, Piotr, Gheorghiade, Mihai, Filippatos, Gerasimos, Krum, Henry, Nowack, Christina, Kolkhof, Peter, Kim, So-Young, Zannad, Faiez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2013
Materias:
Fasttrack Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743070/
https://www.ncbi.nlm.nih.gov/pubmed/23713082
http://dx.doi.org/10.1093/eurheartj/eht187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743070/
https://www.ncbi.nlm.nih.gov/pubmed/23713082
http://dx.doi.org/10.1093/eurheartj/eht187

Ejemplares similares